Results 81 to 90 of about 8,589 (193)

Effects of mental health diagnosis on perceived effects of modafinil.

, 2020
Effects of mental health diagnosis on perceived effects of modafinil.
Nicola Rycroft (8407251), Rachel D. Teodorini (8407248), James H. Smith-Spark (7238594)   +2 more
core   +1 more source

Caffeine and Modafinil Ameliorate the Neuroinflammation and Anxious Behavior in Rats during Sleep Deprivation by Inhibiting the Microglia Activation

Frontiers in Cellular Neuroscience, 2018
Background: Sleep deprivation (SD) plagues modern society due to the professional demands. It prevails in patients with mood and neuroinflammatory disorders.
Meetu Wadhwa, Garima Chauhan, Koustav Roy, Surajit Sahu, Satyanarayan Deep, Vishal Jain, Krishna Kishore, Koushik Ray, Lalan Thakur, Usha Panjwani   +9 more
doaj   +1 more source

Modafinil: Is it ready for prime time?

, 2006
Psychostimulants have been used to treat many symptoms associated with advanced cancer. The primary role of psychostimulants in such cases is the treatment of symptoms such as cancer-related fatigue, opioid-induced sedation, depression, and cognitive ...
Eric Prommer, MD
core   +1 more source

Modafinil for psychostimulant dependence [PDF]

, 2008
Psychostimulant dependence is a major public health issue in many parts of the world associated with a wide range of psychological, medical and social problems.
Shearer, James Douglas
core   +1 more source

Short- and Long-Term Efficacy of Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub Study of the Modafinil in Debilitating Fatigue After Stroke Trial

Frontiers in Neurology, 2018
BackgroundThe phase-II modafinil in debilitating fatigue after stroke trial demonstrated that modafinil improves fatigue and quality of life in severely fatigued stroke survivors.
Thomas P. Lillicrap, Thomas P. Lillicrap, Christopher R. Levi, Christopher R. Levi, Elizabeth Holliday, Mark William Parsons, Mark William Parsons, Andrew Bivard, Andrew Bivard   +8 more
doaj   +1 more source

The use of modafinil for the treatment of fatigue in multiple sclerosis: A systematic review and meta‐analysis of controlled clinical trials

Brain and Behavior
Introduction Multiple sclerosis (MS) is a debilitating neurological condition affecting nearly one million people across the United States. Among the most prominent symptoms of the condition are excessive fatigue and daytime sleepiness. Numerous clinical
Shamas Ghazanfar, Minaam Farooq, Shurjeel Uddin Qazi, Bipin Chaurasia, Ulrike Kaunzner   +4 more
doaj   +1 more source

Microwave coprocessing of modafinil with Gelucire®: Thermal and compression characteristics

ADMET and DMPK
Introduction: Modafinil, a wakefulness-promoting agent, is primarily used to treat excessive daytime sleepiness associated with narcolepsy and fatigue. As a BCS class II drug, modafinil exhibits low solubility and high permeability, with its crystalline
Derar Omari, Assayed Sallam, Iyad Rashid, Shereen M. Assaf, Faisal Akayleh, Khaldoun A. Al-Sou′od   +5 more
doaj   +1 more source

Effect of modafinil on depression associated with neurological disorders.

, 2013
Effect of modafinil on depression associated with neurological disorders.
Xiaowen Wang (15759), Yan Dong (135314), Lijun Hou (465158), Chengguang Huang (492418), Xi Han (391414), Ping Sheng (465159), Xiang Wang (127867), Mingkun Yu (465162)   +7 more
core   +1 more source

Modafinil dependence: A case with attention-deficit/hyperactivity disorder

, 2018
Modafinil is generally known as a drug with low addiction potential. There are few case reports in the literature demonstrating that Modafinil, stated being capable of diminishing symptoms of attention deficit/hyperactivity disorder (ADHD), causes ...
Tümkaya, Selim, Kar, G., Mart, M., Başay, Ömer, Alaçam, Hüseyin   +4 more
core   +1 more source

Modafinil/armodafinil in obstructive sleep apnoea: A systematic review and meta-analysis

, 2016
Modafinil is used internationally to treat residual sleepiness despite continuous positive airway pressure in obstructive sleep apnoea (res-OSA). In 2011, the European Medicines Agency removed the indication based on an unfavourable risk-benefit profile ...
Vakulin, A., Hedner, Jan A,, Yee, B. J., Chapman, J. L., Marshall, N. S.   +4 more
core   +1 more source